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Abstract
Objective: IgG4-related disease is an emerging clinical entity which frequently involves tissue within the orbit. In order to
appreciate the implications of IgG4 immunostaining, we analyzed gene expression and the prevalence of IgG4-
immunostaining among subjects with orbital inflammatory diseases.
Methods: We organized an international consortium to collect orbital biopsies from 108 subjects including 22 with no
known orbital disease, 42 with nonspecific orbital inflammatory disease (NSOI), 26 with thyroid eye disease (TED), 12 with
sarcoidosis, and 6 with granulomatosis with polyangiitis (GPA). Lacrimal gland and orbital adipose tissue biopsies were
immunostained for IgG4 or IgG secreting plasma cells. RNA transcripts were quantified by Affymetrix arrays.
Results: None of the healthy controls or subjects with TED had substantial IgG4 staining. Among the 63 others, the
prevalence of significant IgG4-immunostaining ranged from 11 to 39% depending on the definition for significant. IgG4
staining was detectable in the majority of tissues from subjects with GPA and less commonly in tissue from subjects with
sarcoidosis or NSOI. The detection of IgG4+ cells correlated with inflammation in the lacrimal gland based on histology. IgG4
staining tissue expressed an increase in transcripts associated with inflammation, especially B cell-related genes. Functional
annotation analysis confirmed this.
Conclusion: IgG4+ plasma cells are common in orbital tissue from patients with sarcoidosis, GPA, or NSOI. Even using the
low threshold of 10 IgG4+ cells/high powered field, IgG4 staining correlates with increased inflammation in the lacrimal
gland based on histology and gene expression.
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Introduction
IgG4-related disease (IgG4-RD) was first described in patients
with autoimmune pancreatitis who had elevated concentrations of
IgG4 in serum [1]. Shortly thereafter, in 2003, extra-pancreatic
lesions were described in patients with autoimmune pancreatitis,
which led to the recognition of IgG4-RD as a systemic condition
[2]. Since 2003, IgG4-RD has been described in a multitude of
organ systems including the pancreas, biliary tree, salivary glands,
kidneys, lungs, skin, prostate, and orbit [1,3–7]. Across the various
organ systems, IgG4-RD is known to have a similar histopatho-
logical presentation which includes a dense lymphoplasmacytic
infiltrate that is rich in IgG4+ plasma cells (IgG4+PC), storiform
fibrosis, and obliterative phlebitis [8].
Ophthalmic disease is a common manifestation of IgG4-RD
[9]. Patients with IgG4-immunostaining, may present with
painless eyelid swelling, proptosis, or diplopia [10,11]. The
lacrimal glands, the nasolacrimal duct, and the retrobulbar region
may be affected [7,11–13]. A consensus report recommended the
term, IgG4-related dacryoadenitis for disease in the lacrimal gland
and IgG4-related orbital inflammation for disease that affects
adipose tissue just posterior to the ocular globe [14].
Orbital inflammatory disease can affect orbital muscle, lacrimal
gland, or adipose tissue. The most common systemic disease
associated with orbital inflammation is hyperthyroidism attribut-
able to Graves disease, also known as thyroid eye disease or TED.
Sarcoidosis or granulomatosis with polyangiitis (GPA, previously
known as Wegener’s granulomatosis) can also cause inflammation
within the orbit. Many patients with orbital inflammatory disease
are classified as having nonspecific orbital inflammation (NSOI,
previously known as orbital pseudotumor). Little is known as to
how each of these entities might be related to IgG4-RD.
The etiology of IgG4-RD remains unclear. Although the
infiltration of IgG4+PC is a defining characteristic of the disease,
there is no evidence that IgG4 is directly involved in the
pathogenesis. In fact, some have hypothesized that IgG4, which
does not fix complement, is expressed to dampen inflammation
[15]. Intriguingly, an immune response to IgG4 reportedly
exacerbates rheumatoid arthritis [16].
Three studies that sought to determine the prevalence of IgG4 -
immunostaining among patients with orbital inflammation found
very discrepant results with prevalence ranging from 4 to 52%
[7,17,18]. In part, this relates to the definition of a positive case.
Some studies have used a threshold of 10 IgG4+PC/high powered
field (hpf) [9,18]. Other studies have used thresholds of up to 30
IgG4+cells/hpf or a minimum ratio of IgG4+:IgG+PC of 0.40 or a
combination thereof [11,17]. Some have suggested that IgG4-
immunostaining has immense clinical implications that frequently
indicate a multisystem disease which is highly likely to respond to
rituximab therapy [19,20]. Accordingly an understanding of the
prevalence of IgG4 immunostaining among patients with orbital
inflammation has potential clinical and therapeutic implications.
We sought to clarify the implication of IgG4 immunostaining in
the orbit by studying tissue from patients with a variety of orbital
inflammatory diseases. We correlated the detection of IgG4+
plasma cells in tissue with the specific diagnosis as well as with
inflammation, fibrosis, and gene expression.
Materials and Methods
Human subjects and tissues
This study was approved by the Institutional Review Boards
(IRB) at Oregon Health & Science University, Columbia
University, University of California San Diego, Wake Forest
University, Medical College of Wisconsin, and Mount Carmel
(Ohio) and by the University of British Columbia Clinical
Research Ethics Board, the Royal Adelaide Hospital Research
Ethics Committee, and the King Khaled Eye Specialist Hospital
Human Ethics Committee/Institutional Review Board. This study
was in compliance with the Helsinki Declaration. Formalin-fixed
paraffin-embedded (FFPE) samples were obtained from 9
contributing centers. Data were analyzed anonymously and
written informed consent was obtained when required by the
local IRB or ethics committee.
The diagnoses of nonspecific orbital inflammation, sarcoidosis,
granulomatosis with polyangiitis, thyroid eye disease, and normal
were based on the clinical and histopathological information
obtained and submitted by orbital disease specialists and ocular
pathologists from their respective institutions. Biopsies from a total
of 109 subjects were used (22 controls with no known orbital
disease, 42 NSOI, 6 GPA, 12 sarcoidosis, 26 TED) (Table 1).
Among the 6 subjects with a diagnosis of GPA, the antineutrophil
cytoplasmic antibody (ANCA) test was positive in four of five and
unknown in one. Of those with a positive test, 3 had a cytoplasmic
ANCA pattern. The subject with a negative ANCA had
pulmonary disease in addition to the orbital disease. One other
subject with GPA had renal disease, but the others had a limited
form of GPA. Among the 12 subjects diagnosed with sarcoidosis,
all had non-caseating granulomata present in the lacrimal or
orbital adipose tissue biopsy. Adenopathy was present on chest CT
scan in six. In 5 subjects, results of CT scanning and/or biopsy
outside of the orbit were not known or not performed. The control
tissue was obtained during surgery on eyes with non-inflamed
orbits, such as blepharoplasties and enucleations. Multiple
specimens were evaluated for 7 patients, three of whom had both
orbit and lacrimal gland biopsies. In total there were 119 tissue
biopsies (74 orbital tissue, 45 lacrimal gland) used for histopath-
ological and immunohistochemical analysis.
All samples were reviewed and scored without reference to the
indications for biopsy or other clinical information. Two slides
from each specimen were stained with hematoxylin and eosin for
histopathological evaluation. These features were independently
re-evaluated by two ocular pathologists (D.J.W. and H.E.G.). The
features included degree of fibrosis, degree of inflammation,
presence of obliterative phlebitis, and presence of storiform
fibrosis. The degrees of fibrosis and degree of inflammation were
quantified as absent (0), mild (1), moderate (2), or severe (3). For
most samples, the presence or absence of lacrimal gland tissue was
confirmed by the presence or absence of lacrimal gland mRNA.
Immunohistology
Two serial sections from each specimen were used for
immunohistochemical evaluation. One slide was stained for
IgG4+ plasma cells (antibody from The Binding Site, San Diego,
Ca, 1:15000 dilution) and the other for IgG+ plasma cells
(antibody from Dako, 1:10,000 dilution). Immunostaining used
Ventana automated instruments with Ultraview detection (Ven-
tana, Tucson, AZ). Two surgical pathologists (M.L.T. and D.C.H.)
independently counted the numbers of IgG4+ cells in three high
power fields (hpf, 400X, about 0.3 mm2) and the IgG+ cells in the
corresponding fields of the paired slides. These data are expressed
as the mean number of positive cells per hpf. For the subjects for
whom more than one specimen of the same tissue type was
stained, the overall mean was used for the statistical analysis.
RNA extraction and microarray
For each FFPE specimen, multiple 10 mm sections were
collected and total RNA was extracted with miRNeasy FFPE kits
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(Qiagen, Valencia, CA) according to the manufacturer’s protocol.
RNA concentrations were determined by UV absorbance. RNA
was prepared for microarray analysis using the SensationPlus
FFPE Amplification and 39 IVT Labeling kit (Affymetrix, Santa
Clara, CA). 50 ng of RNA was used for the majority of samples
with a minimum input of 20 ng RNA for samples in which RNA
yields were limited. Biotin-labeled cDNA targets were hybridized
with a GeneChip Human Genome U133 Plus 2.0 array
(Affymetrix, Santa Clara, CA) according to standard Affymetrix
protocol. This array contains over 54,000 probe sets for 47,000
transcripts and variants. Following hybridization, arrays were
stained and scanned using the GeneChip Scanner 3000 7G system
(Affymetrix). Image processing and initial quality control analysis
were performed using Affymetrix GeneChip Command Console
(AGCC) v. 3.1.1 and Affymetrix Expression Console v. 1.1
software, respectively.
Statistical analysis
Simple statistical tests were done with chi-square tests, Mann-
Whitney U-test, or Student’s t-test as appropriate [21]. Affymetrix
CEL files were preprocessed by the Robust Multiarray Analysis.
After normalization, linear models were fitted to test potential
differences in gene expression profiles due to elevated concentra-
tions of IgG4 while controlling for diseases and batch effects. We
used ‘affy’ and ‘limma’ packages of Bioconductor (http://www.
bioconductor.org) in the R project for statistical computing
(http://www.r-project.org).
Results
Altogether, 119 orbital adipose tissue and lacrimal gland tissue
samples from 108 subjects were evaluated (Table 1). Our control
group consisted of 22 subjects without orbital disease. The disease
cases included 26 with TED, 6 with GPA, 42 with NSOI, and 12
with sarcoidosis. Of the 108 subjects, about one third was male.
The collective median reported age at the time of biopsy was 54.0
years (range, 12.0–96.1 years). The ages shown in Table 1 reflect
the behavior of each disease. Healthy control tissue was primarily
available from older subjects and this group is older than each of
the four diseased groups by Mann-Whitney U test (p,0.01).
However, the TED group is also a negative control and does not
differ significantly in age from the other 3 diseased groups.
Furthermore, we found no significant association between age and
positive staining for IgG4 among the subjects with NSOI, GPA, or
sarcoidosis (see below).
IgG4+PCs were rarely seen in tissues from control or TED
subjects (Table 2). The frequency of IgG4+PCs varied consider-
ably among subjects in the other disease groups as illustrated in
Figure S1 in File S1; pairs of images from three subjects with
NSOI show heavy, light, and no staining for IgG4 and IgG. For
the five subjects for whom more than one specimen of the same
tissue type was stained, the mean counts were used for statistical
analysis. When classified with the low threshold of$10 IgG4+PC/
hpf, five of six (83%) GPA cases were IgG4+. Sixteen of 42 (38%)
of NSOI cases were IgG4+, and five of twelve (42%) of sarcoidosis
cases were positive. Only a few cases had counts that met either of
the more stringent thresholds of having at least 30 IgG4+PC/hpf
or at least 40% of the plasma cells being IgG4+ (Table 2).
IgG4+PC infiltration was observed in both lacrimal gland and
orbital adipose tissue samples (Table 2). In total, 11 of 29 (38%)
lacrimal gland tissue samples from non-TED orbital inflammation
patients were found to be IgG4+ based on the least stringent
criterion. 15 of 35 (43%) orbital adipose tissue samples from non-
TED orbital inflammation patients were found to be IgG4+. Both
a lacrimal gland and an orbital adipose tissue sample were studied
for one subject with sarcoidosis. Both of these samples were
determined to be IgG4- and were included in Table 2.
Among the non-TED orbital inflammation cases, there was no
significant correlation between IgG4+ status and gender or the
mean age at biopsy based on IgG4+ immunostaining defined as at
least 10 positive cells per hpf (Table 3). Examining only the NSOI
samples from orbital adipose tissue, there was a trend for IgG4-
samples to come from older subjects, by Mann-Whitney U test
(p = 0.078, excluding one 96.1 year old outlier). There was no real
significant difference in age and IgG4 status for NSOI affecting the
lacrimal gland.
Correlation of IgG4 staining with inflammation or fibrosis
No storiform fibrosis or obliterative phlebitis was noted in any of
the tissue samples. A comparison of the fibrosis and inflammation
scores between IgG4+ and IgG4- cases showed a significant
increase in fibrosis and inflammation in the lacrimal gland tissue
among IgG4+ NSOI patients (Mann-Whitney U test, p = 0.014
and p= 0.005, respectively) (Figure 1). Although in the orbit only
the IgG4- group included samples with IgG4 counts #0.5, these
fibrosis and inflammation scores were not statistically different. For
these comparisons, the correlation relied on the least stringent
criteria to classify IgG4 status.
Correlation of treatment with IgG4 staining
We employed the prescription of corticosteroid or other
immunosuppressive as a surrogate index for severity, reasoning
that more severe disease was more likely to prompt potentially
toxic therapy. Using chi square analysis, patients with NSOI,
GPA, or sarcoidosis who had at least 10 IgG4+cells/hpf were not
more likely to be treated with corticosteroid (p = 0.3) and not more
likely to receive additional immunosuppression after the biopsy
(p = 0.7). A higher percentage of the IgG4+ patients started
corticosteroid treatment prior to their biopsy, whereas the opposite
was true for the IgG4- group (Figure 2). We further compared the
Table 1. Case demographics.
Diagnosis Number of subjects Age Median (Q1–Q3) Male:Female
Control (normal) 22 66.5 (58.9–71.0) 7:15
TED 26 55.0 (44.6–61.0) 7:20
GPA 6 47.1 (27.1–49.0)* 2:04
NSOI 42 48.1 (37.6–64.3) 15:27
Sarcoidosis 12 39.8 (31.7–49.4)* 4:08
*Ages are not available for 4 subjects.
doi:10.1371/journal.pone.0109847.t001
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maximum dose of prednisone given prior to biopsy to those who
were IgG4 + with those who were IgG4 negative. The values
(52.5618.9 mg/day and 55.8627.1 mg/day) respectively did not
differ between the two groups. Six patients received an injection of
triamcinolone as part of their therapy, and these were equally
divided between the IgG4+ and IgG4- groups.
Because no subject with TED had substantial staining for IgG4,
we reviewed the therapy for these subjects in case the absence of
staining was a result of treatment. Of the 26 subjects with TED in
this study, two were receiving prednisone at the time of biopsy, 5
had previously been treated with prednisone between 3.5 months
and 3.5 years before the biopsy, 13 had not received any
medications, and in 6 subjects, the prior treatment was unknown.
Thus treatment is an unlikely explanation for the absence of IgG4
staining among subjects with TED.
IgG4 staining and multisystem disease
IgG4 staining has been proposed as a marker of multisystem
disease [2]. GPA by definition is a multisystem disease and
sarcoidosis tends to involve multiple tissue sites. Fifteen subjects in
our study had NSOI and IgG4 immunostaining. Of these 15, we
were able to review the medical history of 12 in detail. None of
these 12 had evidence for a multisystem disease, including the two
subjects who had greater than 30 IgG4+ cells per hpf and an
IgG4:IgG cell ratio of .0.4.
IgG4 immunostaining and gene expression
We compared RNA transcripts in tissues that stained for IgG4
plasma cells with tissues from subjects with NSOI, GPA, or
sarcoidosis and little or no IgG4 staining. We used a positive
staining threshold of at least 10 IgG4+ cells/hpf and a threshold
for gene expression change of at least 1.5-fold difference with a
false discovery rate adjusted p-value of ,0.05. In lacrimal gland
samples, we detected 98 probes sets with increased signals and 4
that had decreased signals. For tissue from the orbital adipose
tissue, 100 probe sets had increased signals and 22 were decreased.
The complete lists of probe sets indicating significant expression
differences are in Tables S1 and S2 in File S1.
Examples of probe sets with elevated signals in IgG4+ orbital
adipose tissue (Table 4) include several immune response related
genes. Of the 100 probe sets with higher signals in IgG4+ orbital
adipose tissue, 16 are for light or heavy chain immunoglobulin
Table 2. A minority of subjects with inflamed orbits have markedly high IgG4+PC counts.
IgG4+ PC/hpf IgG4+ PC/hpf .30 and IgG4+PC/IgG+PC $0.4
,10 10–29 30–99 $100
Lacrimal Gland
Control 7 - - - -
TED 4 - - - -
NSOI 15 4 2 1 1
Sarcoidosis 3 3 1 - -
Orbital fat
Control 15 - - - -
TED 25 - - - -
GPA 1 1 3 1 4
NSOI 11 2 5 2 2
Sarcoidosis 5 1 - - -
The number of subjects in each category is shown.
doi:10.1371/journal.pone.0109847.t002
Table 3. IgG4 status is independent of age and gender.
IgG4+ IgG4- Sex Ratio (Male:Female)
Median(Q1–Q3) Median(Q1–Q3) IgG4+ IgG4-
Lacrimal Gland
NSOI 44.2(43.3–50.5) 45.9(37.8–61.4) 1.3:1 1:2.8
Sarcoidosis 30.7(21.3–40.0 35.1(32.1–37.5)* 1:3 1:2
Orbital adipose tissue
GPA 48.1(41.3–50.37* 27.1 1:1.5 0:1
NSOI 40.0(35.6–53.5) 69.3(44.2–72.8) 1:2.5 1:2.7
Sarcoidosis —* 53.9(45.0–58.9) 0:1 1:1.5
*Ages are not available for 4 subjects.
doi:10.1371/journal.pone.0109847.t003
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transcripts (Table S1 in File S1). These results are consistent with
the inflammation scores shown in Figure 1 in that higher scores
were more frequent in the IgG4+ tissues. Table 4 also lists
examples of probe sets with lower signals in the IgG4+ orbit
tissues.
Examples of lacrimal gland transcripts with differential expres-
sion in IgG4+ tissues are listed in Table 5. Unlike orbital adipose
tissue, no increased expression of immunoglobulin genes was
detected. This is likely due to high levels of immunoglobulin
transcripts in normal lacrimal gland that might obscure detection
of additional antibody transcripts. Nonetheless, the profile of genes
with increased transcript levels in the IgG4+ lacrimal gland tissues
is consistent with more lymphocytic activity than in the IgG4-
tissues.
Discussion
To our knowledge, our study is the first study to compare the
prevalence of IgG4 staining among various inflammatory condi-
tions within the orbit. A recent report on IgG4 immunostaining in
skin disease similarly concluded that IgG4 staining is detectable in
a variety of clinical entities [22]. Wallace and colleagues [23]
described patients with IgG4 associated pachymeningitis. Their
series included patients who had either meningeal sarcoidosis or
GPA, some of whom stained positively for IgG4 [23]. Strehl and
colleagues found positive IgG4 staining in a variety of conditions
including rheumatoid synovitis and the inflammatory response
around a carcinoma. [24] We believe that ours is the first study to
detect IgG4 immunostaining in tissue from patients with
sarcoidosis affecting the orbit. A report from Japan showed that
nearly 25% of patients with lymphoproliferative disease within the
orbit have IgG4+ cells in orbital tissue [25]. Another study found
that 50% of subjects with xanthogranuloma in the orbit show
IgG4 immunostaining [25]. Chang et al. noted the presence of
IgG4+ plasma cells in GPA patient biopsies taken from various
sites including the majority of periorbital biopsies [26]. Similarly
we reported that renal biopsies from patients with GPA can stain
positively for IgG4 [27].
Considering only the non-TED orbital inflammation cases, we
found the prevalence of IgG4+ immunostaining to be 36% based
on a cutoff of $10 IgG4+PC/hpf. However, this cutoff is
controversial in the literature. In 2008, Sato et al. published one
of the largest IgG4-immunostaining studies [7]. Applying a cutoff
of .10 IgG4+cells/hpf, they found a prevalence of 19% among
patients with ocular adnexal lymphoproliferative disorders. This
paper was criticized for setting too low of a threshold for
determining IgG4 status [28]. Most papers set a minimum
threshold of 30 IgG4+PC/hpf [29]. Using this standard, the
prevalence of IgG4-immunostaining would decrease to 15 of 64
(23%). Alternatively, some studies have used the more stringent
criteria of $10 IgG4+PC/hpf and an IgG4+:IgG+ ratio of $0.4
[7,30]. Using this stringent criterion, the prevalence of IgG4-
immunostaining in our study would be 7 of 64 (11%).
Our study is the first to analyze RNA transcript expression in
tissue that contains IgG4 plasma cells. We based this analysis on
the least stringent definition of IgG4 staining for a practical reason;
other definitions of IgG4 positivity would have provided too few
samples for accurate statistical analysis. We believe that this
analysis lends support for defining significant IgG4 staining within
the orbit using the criterion of at least ten cells staining per hpf.
Unlike the histopathological presentation in IgG4-RD in other
organ systems, we did not find storiform fibrosis or obliterative
phlebitis in any of our samples, regardless of the tissue type. A
Figure 1. Lacrimal tissues from NSOI patients with at least 10 IgG4+ PC/hpf show increased fibrosis and inflammation. IgG4+ orbit
tissues lack the lowest fibrosis and inflammation scores. Each symbol represents the score for one subject. P-values are based on Mann-Whitney
U-test.
doi:10.1371/journal.pone.0109847.g001
Figure 2. Patients with NSOI, GPA or sarcoidosis with at least
10 IgG4+ PC/hpf were not more likely to be treated with
corticosteroid or other immunosuppressive therapy. These
results are based on chi square testing for 30 IgG4- and 17 IgG4+
subjects for whom treatment data were available.
doi:10.1371/journal.pone.0109847.g002
IgG4 in Orbital Inflammatory Disease
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Table 4. Examples of gene expression differences comparing IgG4+ to IgG4- orbital tissue from subjects with NSOI, GPA, or
sarcoidosis.
Probe Set Gene Symbol Fold Change FDR P-value Gene Title
A Gene Ontology
Biological Process
Probe sets with increased levels




3.33 0.029 Immunoglobulin heavy locus Immune response
216829_at IGK; IGKC 3.06 0.013 Immunoglobulin kappa locus;
immunoglobulin kappa constant
Immune response
205242_at CXCL13 2.99 0.045 Chemokine (C-X-C motif) ligand 13 T and B cell chemotaxis
242020_s_at ZBP1 2.80 0.048 Z-DNA binding protein 1 Positive regulation of type I interferon-
mediated signaling pathway
234477_at IGHA1; IGHV4-31 2.52 0.022 Immunoglobulin heavy constant
alpha 1; immunoglobulin heavy
variable 4-31
Immune response
205884_at ITGA4 2.40 0.049 Integrin, alpha 4 (antigen CD49D,
alpha 4 subunit of VLA-4 receptor)
Cell adhesion
217227_x_at IGLV1-44 2.40 0.039 Immunoglobulin lambda variable
1-44
Immune response




211648_at IGHG1; IGHM 1.98 0.034 Immunoglobulin heavy constant
gamma 1; immunoglobulin heavy
constant mu
Immune response
223565_at MZB1 2.13 0.011 Marginal zone B and B1 cell-specific
protein
Positive regulation of immunoglobulin
biosynthetic process
204562_at IRF4 2.08 0.026 Interferon regulatory factor 4 interferon-gamma-mediated signaling
pathway
1558561_at HM13 2.01 0.002 Histocompatibility (minor) 13 Proteolysis
208083_s_at ITGB6 1.96 0.043 Integrin, beta 6 Cell adhesion
201688_s_at TPD52 1.86 0.019 Tumor protein D52 B cell differentiation
225435_at SSR1 1.86 0.020 Signal sequence receptor, alpha Activation of signaling protein activity
involved in unfolded protein response
Probe sets with decreased levels





DUSP1 22.34 21.75 0.038 0.014 Dual specificity phosphatase 1 Inactivation of MAPK activity
210226_at NR4A1 22.27 0.035 Nuclear receptor subfamily 4,
group A, member 1
Positive regulation of endothelial cell
proliferation
207008_at CXCR2 21.82 0.038 Chemokine (C-X-C motif)
receptor 2
Dendritic cell chemotaxis
1559960_x_at SYCE1L 21.77 0.030 Synaptonemal complex central
element protein 1-like
Meiosis
226765_at SPTBN1 21.75 0.047 Spectrin, beta, non-erythrocytic 1 Mitotic cytokinesis
227404_s_at EGR1 21.71 0.044 Early growth response 1 Negative regulation of transcription
from RNA polymerase II promoter
206869_at CHAD 21.68 0.027 Chondroadherin Cartilage condensation
1553572_a_at CYGB 21.67 0.010 Cytoglobin Oxygen transport
208333_at LHX5 21.65 0.025 LIM homeobox 5 Regulation of cell proliferation
216904_at COL6A1 21.64 0.029 Collagen, type VI, alpha 1 Extracellular matrix disassembly
229207_x_at RNF187 21.62 0.017 Ring finger protein 187 Positive regulation of cell proliferation
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Table 4. Cont.
Probe Set Gene Symbol Fold Change FDR P-value Gene Title
A Gene Ontology
Biological Process
1555380_at ADAMTS4 21.62 0.013 ADAM metallopeptidase with
thrombospondin type 1 motif, 4
Skeletal system development
203792_x_at PCGF2 21.61 0.036 Polycomb group ring finger 2 Negative regulation of transcription
from RNA polymerase II promoter
206128_at ADRA2C 21.60 0.043 Adrenoceptor alpha 2C Activation of MAPK activity by
adrenergic receptor signaling pathway
Probe sets were selected for expression increases or decreases and ample annotation. A relevant Gene Ontology Biological Process (http://geneontology.org/) is listed
for each gene.
doi:10.1371/journal.pone.0109847.t004
Table 5. Examples of gene expression differences comparing IgG4+ to IgG4- lacrimal gland tissue from subjects with NSOI, GPA, or
sarcoidosis.
Probe sets with increased levels
Probe Set Gene Symbol FC FDR p value Gene Title Gene Ontology Biological Process
228599_at MS4A1 3.51 0.004 Membrane-spanning
4-domains, A1
B cell activation





0.016 0.028 0.009 CD22 molecule Cell adhesion
219014_at PLAC8 2.83 0.030 Placenta-specific 8 Regulation of cell proliferation





BANK1 2.55 2.44 0.012 0.020 B-cell scaffold protein with
ankyrin repeats 1
B cell activation
221601_s_at FAIM3 2.37 0.023 Fas apoptotic inhibitory
molecule 3
Regulation of apoptotic process
235400_at FCRLA 2.37 0.017 Fc receptor-like A Cell differentiation
1564310_a_at PARP15 2.35 0.047 Poly (ADP-ribose) polymerase
family, member 15
Regulation of transcription
205544_s_at CR2 2.27 0.032 Complement component
receptor 2
Complement receptor mediated signaling
35974_at 204674_at LRMP 2.26 2.19 0.009 0.008 Lymphoid-restricted
membrane protein
Vesicle targeting
211861_x_at CD28 2.18 0.038 CD28 molecule Inflammatory response to antigenic stimulus
Probe sets with decreased levels




202068_s_at LDLR 21.53 0.028 Low density lipoprotein
receptor
Receptor-mediated endocytosis
201148_s_at TIMP3 21.57 0.034 TIMP metallopeptidase
inhibitor 3
Negative regulation of peptidase activity
221747_at TNS1 21.60 0.014 Tensin 1 Fibroblast migration
36829_at PER1 21.61 0.009 Period circadian clock 1 Circadian regulation of gene expression
218245_at TSKU 21.68 0.014 Tsukushi, small leucine rich
proteoglycan
Negative regulation of Wnt receptor signaling
pathway
Probe sets were selected for expression increases of more than 2.1 fold or decreases of more than 1.5 fold, p values ,0.5, and sample annotation. A relevant Gene
Ontology Biological Process (http://geneontology.org/) is listed for each gene.
doi:10.1371/journal.pone.0109847.t005
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consensus statement on the pathology IgG4-RD released in 2012
noted that the lacrimal gland is an exception to the general rule
that storiform fibrosis should be a main criterion for diagnosis
[13].
Only two of the biopsies with IgG4 staining as detected in our
study were previously identified as IgG4 + by the referring center.
As some consider IgG4 to be a marker of more severe disease,
knowledge of IgG4 staining could have prompted more aggressive
therapy which was not an issue in our study in which very few
patients were known to be IgG4+. It is also possible that treatment
with prednisone would diminish the number of IgG4+ cells in a
biopsy. While we cannot exclude this possibility, there was no
statistically significant difference between the rate of IgG4
positivity among those who took prednisone before the biopsy
and those who did not take prednisone.
Most experts consider IgG4-RD a distinct clinical entity that
includes the histological implication of increased fibrosis and the
therapeutic implication of a likely response to rituximab therapy
[12,19,20]. Our data could be interpreted in an alternative way:
IgG4 staining identifies a subset of patients with diagnoses such as
sarcoidosis, GPA, or NSOI. Those patients whose tissue stains for
IgG4 have more inflammation and fibrosis, especially within the
lacrimal gland. Our data cannot exclude a third possibility that
both hypotheses are true: IgG4-immunostaining identifies a subset
of patients with entities such as GPA, sarcoidosis, or NSOI and
IgG4 staining could identify some patients with a syndrome
distinct from GPA, sarcoidosis, or NSOI. Since NSOI already
subsumes a presumed variety of entities, the latter hypothesis
would fail to distinguish NSOI patients who are IgG4+ from the
entity of IgG4-RD. We recently reported that 70% of patients with
orbital inflammatory disease respond favorably to therapy with
rituximab [31]. Thus therapeutic response also might not
consistently distinguish the IgG4+ subset from the IgG4 – subset.
In summary, we conducted a multi-centered, international
study on the prevalence of IgG4-immunostaining in orbital
inflammation allowing us to compare the prevalence of IgG4+
PC infiltration in different entities affecting the orbit. Unfortu-
nately, due to the limitations of our database and incomplete
clinical information, we were unable to examine the relationship
between our cases and IgG4 serum concentrations. In addition, by
the nature of our multi-centered approach, we were reliant on
diagnoses from different institutions. In a minority of instances we
lacked complete information on the therapy or diagnostic
evaluation. Although the clinical implications of IgG4 staining in
the orbit require further investigation, our data support the
rationale to target B cells in therapy. Regardless of whether IgG4-
immunostaining is considered a distinct clinical entity or a subset
of other entities, subjects with an IgG4+ tissue infiltrate display an
identifiable gene expression profile consistent with a heightened
inflammatory response. Our study should help physicians better
interpret the implications of IgG4 staining in orbital tissue.
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